share_log

Changzhou Qianhong BiopharmaLTD (SZSE:002550) Shareholder Returns Have Been Decent, Earning 31% in 3 Years

Changzhou Qianhong BiopharmaLTD (SZSE:002550) Shareholder Returns Have Been Decent, Earning 31% in 3 Years

常州千红生物制药有限公司(深圳证券交易所:002550)股东回报不错,3年内盈利31%
Simply Wall St ·  04/26 20:16

By buying an index fund, you can roughly match the market return with ease. But many of us dare to dream of bigger returns, and build a portfolio ourselves. For example, Changzhou Qianhong Biopharma CO.,LTD (SZSE:002550) shareholders have seen the share price rise 22% over three years, well in excess of the market decline (23%, not including dividends).

通过购买指数基金,您可以轻松地大致匹配市场回报。但是我们中的许多人敢于梦想获得更大的回报,并自己建立投资组合。例如,常州千红生物制药有限公司,LTD(深圳证券交易所:002550)股东的股价在三年内上涨了22%,远远超过了市场的跌幅(23%,不包括股息)。

Since it's been a strong week for Changzhou Qianhong BiopharmaLTD shareholders, let's have a look at trend of the longer term fundamentals.

由于对常州千红生物制药的股东来说,这是强劲的一周,让我们来看看长期基本面的走势。

While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

尽管一些人继续教导高效市场假说,但事实证明,市场是反应过度的动态系统,投资者并不总是理性的。研究市场情绪如何随着时间的推移而变化的一种方法是研究公司股价与其每股收益(EPS)之间的相互作用。

Changzhou Qianhong BiopharmaLTD became profitable within the last three years. So we would expect a higher share price over the period.

常州千红生物制药有限公司在过去三年内实现盈利。因此,我们预计在此期间股价将上涨。

You can see how EPS has changed over time in the image below (click on the chart to see the exact values).

您可以在下图中看到 EPS 随时间推移的变化(点击图表查看确切值)。

earnings-per-share-growth
SZSE:002550 Earnings Per Share Growth April 27th 2024
SZSE: 002550 每股收益增长 2024 年 4 月 27 日

It is of course excellent to see how Changzhou Qianhong BiopharmaLTD has grown profits over the years, but the future is more important for shareholders. This free interactive report on Changzhou Qianhong BiopharmaLTD's balance sheet strength is a great place to start, if you want to investigate the stock further.

看到常州千红生物制药多年来如何实现利润增长当然是件好事,但未来对股东来说更为重要。如果你想进一步调查该股,这份关于常州千红生物制药有限公司资产负债表实力的免费互动报告是一个很好的起点。

What About Dividends?

分红呢?

It is important to consider the total shareholder return, as well as the share price return, for any given stock. Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. Arguably, the TSR gives a more comprehensive picture of the return generated by a stock. In the case of Changzhou Qianhong BiopharmaLTD, it has a TSR of 31% for the last 3 years. That exceeds its share price return that we previously mentioned. This is largely a result of its dividend payments!

重要的是要考虑任何给定股票的股东总回报率和股价回报率。尽管股价回报率仅反映股价的变化,但股东总回报率包括股息的价值(假设已进行再投资)以及任何折扣融资或分拆的收益。可以说,股东总回报率更全面地描述了股票产生的回报。就常州千红生物制药有限公司而言,其过去三年的股东回报率为31%。这超过了我们之前提到的其股价回报率。这在很大程度上是其股息支付的结果!

A Different Perspective

不同的视角

While it's never nice to take a loss, Changzhou Qianhong BiopharmaLTD shareholders can take comfort that , including dividends,their trailing twelve month loss of 8.7% wasn't as bad as the market loss of around 13%. Of course, the long term returns are far more important and the good news is that over five years, the stock has returned 5% for each year. In the best case scenario the last year is just a temporary blip on the journey to a brighter future. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Even so, be aware that Changzhou Qianhong BiopharmaLTD is showing 1 warning sign in our investment analysis , you should know about...

尽管亏损从来都不是一件好事,但常州千红生物制药有限公司的股东可以放心,包括股息在内,他们过去十二个月的8.7%的亏损没有市场损失13%左右那么严重。当然,长期回报要重要得多,好消息是,在过去的五年中,该股每年的回报率为5%。在最好的情况下,去年只是通往更光明未来之旅中的一个暂时阶段。我发现将长期股价视为业务绩效的代表非常有趣。但是,要真正获得见解,我们还需要考虑其他信息。即便如此,请注意,常州千红生物制药有限公司在我们的投资分析中显示了1个警告信号,您应该知道...

Of course Changzhou Qianhong BiopharmaLTD may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

当然,常州千红生物制药有限公司可能不是最好的买入股票。因此,您可能希望看到这批免费的成长股。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

请注意,本文引用的市场回报反映了目前在中国交易所交易的股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发